AI radiology Market Outlook 2026–2034: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines AI radiology, software that analyses medical images such as CT, X-ray and MRI to prioritise urgent cases, detect findings and increasingly draft reports. It tests how fast single purpose tools give way to foundation models and enterprise platforms across imaging departments, and which participants capture value among algorithm developers, imaging equipment vendors, technology providers, hospitals and payers.

Radiology is the largest category of AI enabled medical devices. The FDA list through 30 March 2026 held 1,524 devices, of which 1,163, about 76%, were in radiology, led by GE HealthCare with 130 authorisations, Siemens Healthineers with 89, Philips with 50, Canon with 45, United Imaging with 38, Aidoc with 31 and DeepHealth with 28. The conclusion is that imaging equipment vendors and a few specialist developers hold most authorisations, and a hospital choosing an algorithm often chooses among products from its own scanner supplier.

Foundation models are changing the unit of purchase. Aidoc announced FDA clearance on 21 January 2026 of a comprehensive abdomen CT triage solution built on its CARE foundation model, covering 14 acute indications, of which 11 were newly cleared, with a mean sensitivity of 97% and a mean specificity of 98% across the 11 in the pivotal study and about ten times fewer false alerts than single condition tools, according to the company. The conclusion is that one model replacing a stack of single finding products lowers the alert burden for radiologists, and the buyer moves from buying algorithms one by one to buying a platform.

Capital is flowing to platforms. Aidoc raised a USD 150 million Series E in May 2026 led by Goldman Sachs Alternatives, with General Catalyst, SoftBank Investment Advisors and NVentures taking part, to expand CARE, develop automated draft report creation and widen deployment, after a similar round less than a year earlier. The company reports nearly 2,000 hospitals deployed. The conclusion is that investors expect the value to sit in enterprise platforms that extend from triage to report drafting.

Evidence has not kept pace with authorisation. A review of 691 devices found randomised trial data for only 6, fewer than 1% reported patient health outcomes, and a 2025 study of 950 devices linked 60 to 182 recall events, about 43% within one year of authorisation. The conclusion is that payers and hospitals will ask for outcome evidence before paying for algorithms, and post market monitoring becomes part of the product.

The brief treats AI radiology as an accelerating category with an eight year horizon to 2034. It identifies which applications, regions and operators scale first and what each means for algorithm developers, imaging vendors, technology providers, hospitals and payers. It is a focused 104-page decision brief that presents an indicative trajectory rather than a segmented market model.

AI radiology applies deep learning to CT, X-ray, MRI, ultrasound and mammography images to prioritise urgent cases, detect and measure findings and reduce reading time.

Triage tools flag critical findings such as bleeding or embolism so that they reach the radiologist first, while detection tools mark and quantify lesions.

Foundation models cover many findings in one model and are the basis for automated draft reports, and enterprise platforms host many algorithms in one hospital system.

Uses are emergency triage, cancer screening, quantification, workflow prioritisation and reporting, each under device rules.

The limits are limited outcome evidence, integration with image archives and reporting systems, limited reimbursement and post market performance. The period turns on whether platforms show workflow and outcome benefits that hospitals and payers will fund.

The AI radiology market, covering algorithms, enterprise AI platforms and related software and services used in medical imaging workflows, is valued at USD 1.2–1.8 billion in 2026 and is projected to reach USD 6.71–10.06 billion by 2034, at a CAGR of 24%.

The 2026 base rests on algorithms, enterprise AI platforms and related software and services sold to hospitals, imaging networks and imaging vendors. Growth then follows multi-finding clearances, platform adoption and reimbursement.

The forecast is sensitive to outcome evidence, reimbursement and the strategy of imaging vendors. Regionally, North America leads on authorisations and deployments, Europe on health system programmes and the EU AI Act, and Asia-Pacific on imaging vendors and developers in China, Japan, South Korea and India.

The base case assumes foundation models extend to most CT and X-ray workflows and hospitals consolidate on a few platforms, giving the inflection in 2029. An accelerated case assumes early reimbursement and clearance of draft report tools, bringing the inflection to 2028 and lifting the 2034 value to the top of the range. A delayed case assumes outcome evidence and recalls slow purchasing, holding growth at the bottom of the range.

Growth drivers

• FDA authorised algorithms.
• Radiologist workload and shortage.
• Enterprise AI platforms in hospitals.
• Foundation models covering many findings.

Enablers

• Breakthrough Device designation and clearance pathways.
• Hospital and vendor partnerships.
• Cloud compute and GPU capacity.
• Venture and strategic funding.

Restraints and barriers

• Limited randomised and outcome evidence.
• Integration with PACS and reporting systems.
• Limited reimbursement.
• Recalls and post market performance.

The direction of AI radiology is set by radiologist shortage and imaging volume growth, regulation and reimbursement, foundation models and new algorithms, partnering among hospitals, imaging vendors and algorithm developers, and compute and platform cost.

The key participants in AI radiology include Aidoc Medical, Ltd., Lunit Inc., GE HealthCare Technologies Inc., Siemens Healthineers AG, Koninklijke Philips N.V., Canon Inc., United Imaging Healthcare Co., Ltd., RadNet, Inc., Viz.ai, Inc., Rad AI, Inc., Harrison.ai Pty Ltd, Qure.ai Technologies Limited, Microsoft Corporation, NVIDIA Corporation, FUJIFILM Holdings Corporation, Agfa-Gevaert N.V., Sectra AB, Hologic, Inc., Bayer AG, Subtle Medical, Inc., American College of Radiology, Radiological Society of North America, Mayo Clinic, Stanford University, Mass General Brigham, Cleveland Clinic, Johns Hopkins University, Radboud University Medical Center, Karolinska Institutet, NHS England, Royal College of Radiologists, European Society of Radiology, National Institutes of Health, National Electrical Manufacturers Association, U.S. Food and Drug Administration, Centers for Medicare & Medicaid Services, Medicines and Healthcare products Regulatory Agency, European Commission, National Medical Products Administration and Pharmaceuticals and Medical Devices Agency.

The brief profiles representative participants in each archetype and assesses which are positioned to lead as AI radiology matures.

GE HealthCare, Siemens Healthineers, Philips, Canon and United Imaging hold the most authorisations among imaging vendors, Aidoc, Lunit, Viz.ai, Rad AI, Harrison.ai and Qure.ai lead among specialist developers, and RadNet operates imaging centres with its own algorithms. Microsoft and NVIDIA supply models and compute. Competitive intensity is high in 2026 and rises as foundation models spread.

Where value migrates.

In 2026 value sits with developers that hold many clearances and hospital reach, and with imaging vendors whose installed base carries their own algorithms, because hospitals buy tools that are cleared and fit existing systems. By 2029 it moves toward enterprise platforms with foundation models and draft report generation, because buyers want one contract and fewer alerts. By 2034 it settles in AI embedded in imaging systems and reporting. Margins hold for platforms with broad clearances and workflow integration and narrow for single finding tools.

The signals converge on authorisations, platforms and capital. About 76% of FDA listed AI devices are in radiology, a 14 indication foundation model tool was cleared in January 2026, and a USD 150 million round followed in May 2026. Each signal supports growth, and thin outcome evidence, integration and reimbursement limit the pace.

Structural limits show where progress could slow: limited randomised and outcome evidence, integration with image archives and reporting systems, limited reimbursement, and recalls. The brief therefore tracks four indicators: clearances of multi-finding tools, hospital platform deployments, reimbursement decisions, and studies analysed.

Emergency triage first, then screening and quantification, then draft reporting are the expected order of adoption.